Top Biotech News (21 Mar 2025)

US Scientists Eye Foreign Positions Amid Uncertainty

Summary:

American researchers increasingly seek opportunities abroad due to political uncertainty, with some countries like France actively recruiting while others face funding limitations to absorb the potential exodus.

Lab Researchers Fight Plastic Waste with Simple Solutions

Summary:

Graduate students quantified plastic waste from DNA extraction (over 7.5kg from 96 samples) and implemented practical sustainability measures like reusing pipette tips and cleaning tubes, reducing waste by 50%.

FDA Clears First In Vivo Gene Editing Therapy for Hepatitis B

Summary:

Precision BioSciences’ PBGENE-HBV, designed to eliminate chronic hepatitis B by targeting viral DNA in liver cells, received FDA clearance to expand its ELIMINATE-B clinical trial to the US after showing promising early results.

Mirador’s Precision Approach to Immune-Inflammatory Diseases

Summary:

Stealth biotech Mirador, backed by $400M, shifts from external acquisitions to internal innovation with 5-6 programs advancing toward clinical trials, potentially filing 3-4 INDs in 2025 for novel immune-inflammatory therapies.

Fatal Liver Injury Prompts Sarepta to Update DMD Gene Therapy Label

Summary:

Sarepta reports death from acute liver failure in patient using Duchenne muscular dystrophy gene therapy Elevidys. Despite this unprecedented severity, company maintains positive benefit-risk profile while updating safety information.

Subscribe to the latest updates in the newsletter

Share your disease area, therapeutic candidate and research objectives.

Related Solutions

Organoid Service
Research Service
Technical Service

ODISEI CNS - Human brain & retinal organoid
solutions for translational CNS discovery.

Please provide the information below, and our team will contact you shortly with brochure and relevant case studies.

Thank you for your submission.

Our team has received your request and will get back to you shortly.
If you do not receive our confirmation email, kindly check your spam or junk folder.